Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia

Abstrakt

The effects of lipid-lowering treatment were evaluated in patients with schizophrenia treated with antipsychotics. Forty-six patients with schizophrenia and with severe dyslipidaemia were examined at baseline and three months after initiation of statin therapy.

A significant decrease in triglycerides, total cholesterol, low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and in associated ratios was observed. No significant changes occurred in components of metabolic syndrome other that triglycerides